Journals / Turkish Journal of Gastroenterology / 2016 / Cilt: 27 - Sayı: 6

Factors associated with elevated serum chromogranin A levels in patients with autoimmune gastritis STOMACH

Pages
515–520
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum chromogranin A levels maybe helpful in distinguishing autoimmune gastritis patients and gastric carcinoid type I from the control group, but not useful in the differentiation of individuals with autoimmune gastritis from patients with gastric carcinoids.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Chromogranin A is an important tool in the diagnosis of neuroendocrine tumors.
📊
Key Findings & Data:Chromogranin A is also elevated in autoimmune gastritis patients with a different level of increase in each patient.
💡
Conclusion & Impact:Serum chromogranin A levels maybe helpful in distinguishing autoimmune gastritis patients and gastric carcinoid type I from the control group, but not useful in the differentiation of individuals with autoimmune gastritis from patients with gastric carcinoids.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Chromogranin A is an important tool in the diagnosis of neuroendocrine tumors. Autoimmune gastritis is an autoimmune disorder marked by hypergastrinemia, which stimulates enterochromaffinlike cell proliferation. Chromogranin A is also elevated in autoimmune gastritis patients with a different level of increase in each patient. The goal of this study is to explore constituents that influence serum chromogranin A levels in autoimmune gastritis patients.Materials and Methods: One hundred and eighty-eight autoimmune gastritis patients and 20 patients with type I gastric carcinoid tumors were analyzed retrospectively and compared to 110 functional dyspepsia patients in terms of factors that might affect serum chromogranin A levels.Results: The mean serum chromogranin A level was 171.17±67.3 ng/mL in autoimmune gastritis patients (n=62) without enterochromaffin-like cell hyperplasia, and 303.3±102.82 ng/mL in patients (n=126) with enterochromaffin-like cell hyperplasia (p<0.001). The presence of corpus atrophy (p=0.026, OR: 5.03, CI 95%: 1.21-20.88, ?=1.61) and presence of enterochromaffin-like cell hyperplasia (p=0.017, OR: 6.59, CI 95%: 1.4-31.08, ?=1.88) were found as risk factors associated with serum chromogranin A level.Conclusion: Factors influencing raised serum chromogranin A levels in autoimmune gastritis were the presence of ECL cell hyperplasia and serum gastrin levels. Serum chromogranin A levels maybe helpful in distinguishing autoimmune gastritis patients and gastric carcinoid type I from the control group, but not useful in the differentiation of individuals with autoimmune gastritis from patients with gastric carcinoids.

🔖

Cite This Article

KALKAN, Ç., KARAKAYA, M. F., SOYKAN, A. İ. (2016). Factors associated with elevated serum chromogranin A levels in patients with autoimmune gastritis STOMACH. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 6, 515–520. https://ajindex.com/articles/409340

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013
  2. [CrossRef] Bordi C, D'Adda T, Azzoni C, Pilato FP, Caruana P. Hypergastrinemia and gastric enterochromaffin- like cells. Am J Surg Pathol 1995
  3. 19(Suppl 1): S8-19. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperpla- sia and carcinoid tumors in pernicious anemia. Gastroenterology 1985
  4. [CrossRef] Sjoblom SM, Sipponen P, Miettinen M, Karonen SL, Jrvinen HJ. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy 1988
  5. [CrossRef] Stockbrugger RW, Menon GG, Beilby JO, Mason RR, Cotton PB. Gastroscopic screening in 80 patients with pernicious anaemia. Gut 1983
  6. [CrossRef] Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis pa- tients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastro- enterol Hepatol 2001
  7. [CrossRef] Delle Fave G1, Kwekkeboom DJ, Van Cutsem E, et al
  8. Barcelona Consensus Conference participants. ENETS Consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012
  9. [CrossRef] Gough DB, Thompson GB, Crotty TB, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hy- pergastrinemia. World J Surg 1994
  10. [CrossRef] Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991
  11. [CrossRef] Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chro- mogranin A: its clinical value as marker of neuroendocrine tu- mors. Eur J Clin Invest 1998
  12. [CrossRef] Bashir S, Gibril F, Ojeaburu JV, et al. Prospective study of the abil- ity of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther 2002
  13. [CrossRef] Sanduleanu S, De Bruine A, Stridsberg M, et al. Serum chromogra- nin A as a screening test for gastric enterochromaffin- like cell hyperplasia during acid - suppressive therapy. Eur J Clin Invest 2001
  14. [CrossRef] Stabile BE, Howard TJ, Passarro E Jr, O'Connor DT. Source of plas- ma chromogranin A elevation in gastrinoma patients. Arch Surg 1990
  15. [CrossRef] Vargas JA, Alvarez-Mon M, Manzano L, et al. Functional defect of T ce